hanks to the continuous growth of its investments in China, Mexico and Portugal, and the excellent performance of the genetics business and its commercial platforms, during the first quarter of 2021 the Company's EBITDA reached US $ 51.74 million, increasing by 106.39% compared to the US $ 25.07 million registered in the same period of the previous year.,